Janssen submits Genmab-developed drug for EMA approval

Shortly after applying for US marketing approval for drug candidate teclistamab, which is based on Genmab’s duobody platform, the US-based pharmaceutical firm has followed this up with a European application with the EMA.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by ULRICH QUISTGAARD, translated by daniel pedersen

The European Medicines Council (EMA) has just received a new marketing authorization application for teclistamab, a treatment for relapsed or refractory multiple myeloma, which is a type of bone marrow cancer.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading